{"brief_title": "Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer", "brief_summary": "This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.", "condition": "Prostatic Neoplasms", "intervention_type": "Drug", "intervention_name": "Atrasentan", "criteria": "Inclusion Criteria: - Have been diagnosed with prostate cancer. - Have a rising PSA while on hormone therapy or following surgical castration. Exclusion Criteria: - Have evidence of distant metastatic disease on screening bone scan or CT scan. - Have received cytotoxic chemotherapy. - Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.", "gender": "Male", "minimum_age": "19 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00036556.xml"}